Pediatric Clinics of North America - CIPERJ

498 HEENEY & WARE
children with SCD. We appreciate their insights and advice regarding the
optimal use of hydroxyurea in this patient population.
References
[1] Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk
factors. N Engl J Med 1991;325(1):11–6.
[2] Steinberg MH, Rosenstock W, Coleman MB, et al. Effects of thalassemia and microcytosis
on the hematologic and vasoocclusive severity of sickle cell anemia. Blood 1984;63(6):
1353–60.
[3] Baum KF, Dunn DT, Maude GH, et al. The painful crisis of homozygous sickle cell disease.
A study of the risk factors. Arch Intern Med 1987;147(7):1231–4.
[4] Phillips G Jr, Coffey B, Tran-Son-Tay R, et al. Relationship of clinical severity to packed cell
rheology in sickle cell anemia. Blood 1991;78(10):2735–9.
[5] Powars DR. Sickle cell anemia: beta s-gene-cluster haplotypes as prognostic indicators of
vital organ failure. Semin Hematol 1991;28(3):202–8.
[6] Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and
risk factors for early death. N Engl J Med 1994;330(23):1639–44.
[7] Charache S. Fetal hemoglobin, sickling, and sickle cell disease. Adv Pediatr 1990;37:1–31.
[8] Wood WG. Increased HbF in adult life. Baillieres Clin Haematol 1993;6(1):177–213.
[9] Serjeant GR. Fetal haemoglobin in homozygous sickle cell disease. Clin Haematol 1975;4(1):
109–22.
[10] Wood WG, Stamatoyannopoulos G, Lim G, et al. F-cells in the adult: normal values and
levels in individuals with hereditary and acquired elevations of Hb F. Blood 1975;46(5):
671–82.
[11] Watson J, Stahman AW, Bilello FP. Significance of paucity of sickle cells in newborn negro
infants. Am J Med Sci 1948;215:419–23.
[12] Steinberg MH. Compound heterozygous and other hemoglobinopathies. In: Steinberg MH,
Forget BG, Higgs DR, editors. Disorders of hemoglobin: genetics, pathophysiology, and
clinical management. Cambridge (UK): Cambridge University Press; 2001. p. 786–810.
[13] Odenheimer DJ, Sarnaik SA, Whitten CF, et al. The relationship between fetal hemoglobin
and disease severity in children with sickle cell anemia. Am J Med Genet 1987;27(3):525–35.
[14] Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death
in patients with sickle cell disease. N Engl J Med 2004;350(9):886–95.
[15] Powars DR, Schroeder WA, Weiss JN, et al. Lack of influence of fetal hemoglobin levels or
erythrocyte indices on the severity of sickle cell anemia. J Clin Invest 1980;65(3):732–40.
[16] Powars DR, Weiss JN, Chan LS, et al. Is there a threshold level of fetal hemoglobin that ameliorates
morbidity in sickle cell anemia Blood 1984;63(4):921–6.
[17] Leikin SL, Gallagher D, Kinney TR, et al. Mortality in children and adolescents with sickle
cell disease. Cooperative Study of Sickle Cell Disease. Pediatrics 1989;84(3):500–8.
[18] Ley TJ, DeSimone J, Noguchi CT, et al. 5-Azacytidine increases gamma-globin synthesis
and reduces the proportion of dense cells in patients with sickle cell anemia. Blood 1983;
62(2):370–80.
[19] DeSimone J, Koshy M, Dorn L, et al. Maintenance of elevated fetal hemoglobin levels by
decitabine during dose interval treatment of sickle cell anemia. Blood 2002;99(11):3905–8.
[20] Koshy M, Dorn L, Bressler L, et al. 2-Deoxy 5-azacytidine and fetal hemoglobin induction in
sickle cell anemia. Blood 2000;96(7):2379–84.
[21] Saunthararajah Y, Hillery CA, Lavelle D, et al. Effects of 5-aza-2 0 -deoxycytidine on fetal
hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle
cell disease. Blood 2003;102(12):3865–70.
[22] Atweh GF, Sutton M, Nassif I, et al. Sustained induction of fetal hemoglobin by pulse
butyrate therapy in sickle cell disease. Blood 1999;93(6):1790–7.